Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00877500
- Locations
- 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 168
- Registration Number
- NCT00866905
- Locations
- 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸Aventura Medical Center, Aventura, Florida, United States
Phase I Combination Ixabepilone + Cisplatin
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 30
- Registration Number
- NCT00832117
- Locations
- 🇺🇸
The Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇮🇹Local Institution, Viterbo, Italy
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Brown University
- Target Recruit Count
- 16
- Registration Number
- NCT00828308
- Locations
- 🇺🇸
Miriam Hospital, Providence, Rhode Island, United States
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 83
- Registration Number
- NCT00825734
- Locations
- 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸St. Louis Cancer Care, Chesterfield, Missouri, United States
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00821886
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 5
- Registration Number
- NCT00804310
- Locations
- 🇺🇸
Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 111
- Registration Number
- NCT00798252
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2011-05-18
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 64
- Registration Number
- NCT00790894
- Locations
- 🇬🇷
Hygeia Hospital, Second Department of Medical Oncology, Athens, Greece
🇬🇷Alexandra Hospital, Department of Clinical Therapeutics, Athens, Greece
🇬🇷Hippokration General Hospital, Oncology Department, Athens, Greece
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 799
- Registration Number
- NCT00785291
- Locations
- 🇺🇸
Altru Cancer Center, Grand Forks, North Dakota, United States
🇺🇸Saint Vincent Frontier Cancer Center, Billings, Montana, United States
🇺🇸Mercy Hospital Springfield, Springfield, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.